TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Positive Airway Pressure for the Treatment of Acute Ischemic Stroke: A Feasibility Pilot Study
Brief Summary: New stroke therapies are needed. This study seeks to provide the preliminary data needed to plan a future study that will evaluate the efficacy of using continuous positive airway pressure (CPAP) to treat stroke patients who have sleep apnea. Our goal is to use this therapy to reduce stroke symptom severity.


Options:
A: Intervention Type: PROCEDURE; Name: continuous positive airway pressure; Assigned to Arm(s): N/A
B: Arm Label: Telemedicine Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP AirSense™ 10(Resmed) | Arm Label: Standard Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP AirSense™ 10(Resmed) | Intervention Type: DEVICE; Name: Auto CPAP AirSense™ 10(Resmed); Assigned to Arm(s): Standard Group, Telemedicine Group
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-driven intervention | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Peer-driven intervention; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Arm 2
D: Arm Label: Enhanced education and Enhanced follow up; Type: EXPERIMENTAL; Interventions: Other: Enhanced education, Other: Usual follow up | Arm Label: Usual education and Usual follow up; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual education, Other: Enhanced follow up | Arm Label: Enhanced education and Usual follow up; Type: EXPERIMENTAL; Interventions: Other: Enhanced education, Other: Enhanced follow up | Arm Label: Usual education with Enhanced follow up; Type: EXPERIMENTAL; Interventions: Other: Usual education, Other: Usual follow up | Intervention Type: OTHER; Name: Enhanced education; Assigned to Arm(s): Enhanced education and Enhanced follow up, Enhanced education and Usual follow up | Intervention Type: OTHER; Name: Usual education; Assigned to Arm(s): Usual education and Usual follow up, Usual education with Enhanced follow up | Intervention Type: OTHER; Name: Usual follow up; Assigned to Arm(s): Enhanced education and Enhanced follow up, Usual education with Enhanced follow up | Intervention Type: OTHER; Name: Enhanced follow up; Assigned to Arm(s): Enhanced education and Usual follow up, Usual education and Usual follow up

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI)
Brief Summary: The purpose of this study is to establish if a strategy of EBCPAP application in a subgroup of VLBWI, 800 to 1500g birthweight, decreases the need for mechanical ventilation in this group, without affecting mortality.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Poractant alfa (Curosurf®) | Intervention Type: DRUG; Name: Poractant alfa (Curosurf®); Assigned to Arm(s): 2
B: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
C: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen
D: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI)
Brief Summary: The purpose of this study is to establish if a strategy of EBCPAP application in a subgroup of VLBWI, 800 to 1500g birthweight, decreases the need for mechanical ventilation in this group, without affecting mortality.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Very early surfactant and bubble NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: bubble NCPAP | Intervention Type: OTHER; Name: Very early surfactant and bubble NCPAP; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: bubble NCPAP; Assigned to Arm(s): 2
B: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group
C: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
D: Arm Label: Surfactant and Low Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: Surfactant and High Oxygen; Type: EXPERIMENTAL; Interventions: Drug: Surfactant, Drug: Supplemental oxygen with target saturation of 91 to 95% | Arm Label: CPAP and Low Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 85 to 89% | Arm Label: CPAP and High Oxygen; Type: EXPERIMENTAL; Interventions: Device: Continuous Positive Airway Pressure (CPAP), Drug: Supplemental oxygen with target saturation of 91 to 95% | Intervention Type: DRUG; Name: Surfactant; Assigned to Arm(s): Surfactant and High Oxygen, Surfactant and Low Oxygen | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): CPAP and High Oxygen, CPAP and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 85 to 89%; Assigned to Arm(s): CPAP and Low Oxygen, Surfactant and Low Oxygen | Intervention Type: DRUG; Name: Supplemental oxygen with target saturation of 91 to 95%; Assigned to Arm(s): CPAP and High Oxygen, Surfactant and High Oxygen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI)
Brief Summary: The purpose of this study is to establish if a strategy of EBCPAP application in a subgroup of VLBWI, 800 to 1500g birthweight, decreases the need for mechanical ventilation in this group, without affecting mortality.


Options:
A: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Very early surfactant and bubble NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: bubble NCPAP | Intervention Type: OTHER; Name: Very early surfactant and bubble NCPAP; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: bubble NCPAP; Assigned to Arm(s): 2
C: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Poractant alfa (Curosurf®) | Intervention Type: DRUG; Name: Poractant alfa (Curosurf®); Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Bubble CPAP (EBCPAP) in Very Low Birth Weight Infants (VLBWI)
Brief Summary: The purpose of this study is to establish if a strategy of EBCPAP application in a subgroup of VLBWI, 800 to 1500g birthweight, decreases the need for mechanical ventilation in this group, without affecting mortality.


Options:
A: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Increasing use of Antenatal Corticosteroids (ACS) | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Increasing use of Antenatal Corticosteroids (ACS); Assigned to Arm(s): Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Very early surfactant and bubble NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: bubble NCPAP | Intervention Type: OTHER; Name: Very early surfactant and bubble NCPAP; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: bubble NCPAP; Assigned to Arm(s): 2
C: Intervention Type: DEVICE; Name: Early Bubble CPAP; Assigned to Arm(s): N/A
D: Arm Label: PS Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: PS Group | Arm Label: NCPAP Group; Type: EXPERIMENTAL; Interventions: Device: NCPAP Group | Arm Label: ISX Group; Type: EXPERIMENTAL; Interventions: Drug: ISX Group | Intervention Type: DRUG; Name: PS Group; Assigned to Arm(s): PS Group | Intervention Type: DEVICE; Name: NCPAP Group; Assigned to Arm(s): NCPAP Group | Intervention Type: DRUG; Name: ISX Group; Assigned to Arm(s): ISX Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
Brief Summary: This study is a double-blind study to evaluate the efficacy and safety of NV1FGF, a pCOR plasmid constructed by inserting the gene coding for the FGF compared to placebo in patients with severe Peripheral Arterial Occlusive Disease, Fontaine's stage IV. The efficacy was assessed by the complete healing of at least one ulcer in the treated limb, 25 week post-baseline and secondary by the rate of amputation and death.


Options:
A: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
B: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg
C: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo
D: Arm Label: A: GM-CSF + supervised treadmill exercise therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Treadmill Exercise Therapy, Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: B: GM-CSF + attention control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Health education sessions (Control), Drug: granulocyte macrophage colony stimulating factor (GM-CSF) | Arm Label: C: placebo + supervised exercise therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Treadmill Exercise Therapy | Arm Label: D: placebo + attention control group; Type: PLACEBO_COMPARATOR; Interventions: Other: Health education sessions (Control) | Intervention Type: BEHAVIORAL; Name: Supervised Treadmill Exercise Therapy; Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, C: placebo + supervised exercise therapy | Intervention Type: OTHER; Name: Health education sessions (Control); Assigned to Arm(s): B: GM-CSF + attention control group, D: placebo + attention control group | Intervention Type: DRUG; Name: granulocyte macrophage colony stimulating factor (GM-CSF); Assigned to Arm(s): A: GM-CSF + supervised treadmill exercise therapy, B: GM-CSF + attention control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease.
Brief Summary: This study is a double-blind study to evaluate the efficacy and safety of NV1FGF, a pCOR plasmid constructed by inserting the gene coding for the FGF compared to placebo in patients with severe Peripheral Arterial Occlusive Disease, Fontaine's stage IV. The efficacy was assessed by the complete healing of at least one ulcer in the treated limb, 25 week post-baseline and secondary by the rate of amputation and death.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Genetic: HGF plasmid | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Genetic: HGF plasmid | Intervention Type: GENETIC; Name: HGF plasmid; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: Neovasculgen®; Type: EXPERIMENTAL; Interventions: Drug: Neovasculgen® | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neovasculgen® | Intervention Type: DRUG; Name: Neovasculgen®; Assigned to Arm(s): Neovasculgen®, standard care
C: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Middle Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (Placebo Control) | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Middle Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): High Dose | Intervention Type: OTHER; Name: Saline (Placebo Control); Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism
Brief Summary: The aim of the present study was to examine the influence of memantine, a noncompetitive NMDA receptor blocker, in depression co-morbid with long term alcohol heavy use comparing to SSRI-inhibitor, escitalopram. Second goal is to compare their influence to cognitive tasks and the third goal is to follow up alcohol-use with these two medicines.


Options:
A: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Ebixa (memantine hydrochloride); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cipralex (escitalopram); Assigned to Arm(s): N/A
C: Arm Label: Sertraline; Type: EXPERIMENTAL; Interventions: Drug: sertraline (Zoloft) | Arm Label: Naltrexone; Type: EXPERIMENTAL; Interventions: Drug: naltrexone (Revia) | Arm Label: Nal/Sert; Type: EXPERIMENTAL; Interventions: Drug: naltrexone (Revia), Drug: sertraline (Zoloft) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: naltrexone (Revia); Assigned to Arm(s): Nal/Sert, Naltrexone | Intervention Type: DRUG; Name: sertraline (Zoloft); Assigned to Arm(s): Nal/Sert, Sertraline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase Four Double-Blind Randomized Comparative Study on Thestudy on the Efficacy of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism
Brief Summary: The aim of the present study was to examine the influence of memantine, a noncompetitive NMDA receptor blocker, in depression co-morbid with long term alcohol heavy use comparing to SSRI-inhibitor, escitalopram. Second goal is to compare their influence to cognitive tasks and the third goal is to follow up alcohol-use with these two medicines.


Options:
A: Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline
B: Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: BuproprionSR; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: buspirone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mirtazapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tranylcypromine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: VenlafaxineXR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: T3 (Triiodothyronine); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: Ebixa (memantine hydrochloride); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cipralex (escitalopram); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Efficacy and Safety of Nicotine-Qbeta (NicQb) Vaccine Versus Placebo in Healthy Smokers
Brief Summary: The purpose of this study is to help smokers quitting by vaccinating them with CYT002-NicQb. Upon vaccination, the smoker will generate antibodies directed against free nicotine. The antibodies will bind nicotine and prevent its passage into the brain. The successfully vaccinated smoker will have no reward effect after smoking, thus braking the vicious circle of nicotine addiction.


Options:
A: Arm Label: Placebo vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo vaccine | Arm Label: NicVAX vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX vaccine | Intervention Type: BIOLOGICAL; Name: Placebo vaccine; Assigned to Arm(s): Placebo vaccine
B: Arm Label: NicVAX; Type: EXPERIMENTAL; Interventions: Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®) | Arm Label: NicVAX Lot 2; Type: EXPERIMENTAL; Interventions: Biological: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®) | Intervention Type: BIOLOGICAL; Name: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®); Assigned to Arm(s): NicVAX, NicVAX Lot 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Biological: NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: NicVAX conjugate vaccine; Assigned to Arm(s): 1, 2, 3, 4, 6 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): 5
D: Arm Label: NicQb vaccine; Type: EXPERIMENTAL; Interventions: Biological: CYT002-NicQb | Arm Label: Placebo vaccine; Type: PLACEBO_COMPARATOR; Interventions: Biological: CYT002-NicQb | Intervention Type: BIOLOGICAL; Name: CYT002-NicQb; Assigned to Arm(s): NicQb vaccine, Placebo vaccine

Answer: D